SoftOx Solutions AS (OSL:SOFTX)

Market Cap	183.63M +181.8%
Revenue (ttm)	13.59M +795.3%
Net Income	-3.00M
EPS	n/a
Shares Out	2.44B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	73,237,370
Average Volume	33,434,749
Open	0.0638
Previous Close	0.0628
Day's Range	0.0622 - 0.0770
52-Week Range	0.0290 - 0.1745
Beta	2.19
RSI	60.42
Earnings Date	Mar 25, 2026

About SoftOx Solutions AS

SoftOx Solutions AS, together with its subsidiaries, operates as a clinical-stage pharmaceutical company that develops antimicrobials products for infection prevention and treatment in Norway. The company develops SoftOx Inhalation Solution, an inhalation solution that is phase II clinical trial for the treatment of ventilator associated pneumonia and other airway infections. It also developing pan antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. SoftOx Solutions AS was founded in 2012 and is headquartered in Fornebu, Norwa...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 2
• Stock Exchange: Oslo Børs
• Ticker Symbol: SOFTX

Financial Performance

In 2024, SoftOx Solutions AS's revenue was 7.91 million, an increase of 13.38% compared to the previous year's 6.98 million. Losses were -42.94 million, 8.86% more than in 2023.